Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer

Inclusion Criteria:

• Pathologically confirmed colorectal cancer. Immunohistochemistry (IHC) assessmentshows GCC expression in tumor lesions of ≥1+ in an average of over 40% of the area (evaluated by randomly selecting at least five tumor regions).

Patients with metastatic colorectal cancer who have failed second-line treatment.

At least one measurable extracranial lesion per RECIST version 1.1 criteria. Expected survival of ≥90 days.

Normal function of major organs, meeting the following criteria:

1. ECOG performance status of 0-1 or KPS score >70.

2. Hematology parameters meeting: Hemoglobin (HB) ≥80 g/L, Absolute Neutrophil Count (ANC) ≥1.5 × 10^9/L, Platelets (PLT) ≥80 × 10^9/L, Lymphocytes (LY) ≥0.5 × 10^9/L.

3. Biochemistry parameters meeting: Total Bilirubin (TBIL) ≤2.0 × ULN (upper limit ofnormal); ALT and AST ≤2.5 × ULN; Serum Creatinine (Cr) ≤1 × ULN, CreatinineClearance Rate >40 mL/min (by Cockcroft-Gault formula).

4. Left ventricular ejection fraction >55%. Women of childbearing potential must have anegative pregnancy test (serum or urine) within 7 days prior to enrollment and agreeto use appropriate contraception during the study and for 8 weeks after the lastCAR-T administration (women who have undergone sterilization or have beenpostmenopausal for at least 2 years are considered not of childbearing potential).

Voluntary participation in the study, with signed informed consent, good compliance, and willingness to cooperate with follow-up.

Exclusion Criteria:

• Pregnant or lactating women. Receipt of small molecule chemotherapy, targetedagents, other investigational drugs, or monoclonal antibodies within 14 days priorto cell collection for enrollment.

Participation in other clinical trials within 4 weeks prior to the start of this study.

Uncontrolled hypertension that cannot be adequately managed with a single antihypertensive drug (systolic BP >160 mmHg, diastolic BP >100 mmHg), myocardial ischemia or infarction of grade ≥1, arrhythmia of grade ≥1 (including QT interval ≥440 ms), or cardiac insufficiency.

Long-standing, unhealed wounds or fractures. History of substance abuse that cannot be discontinued or a history of psychiatric disorders.

Severe intestinal adhesions, bowel obstruction, or conditions that may cause bowel perforation or abdominal wall fistula after treatment.

Uncontrolled or active fungal, bacterial, viral, or other infections. Grade ≥2 hematologic toxicity or grade ≥3 non-hematologic toxicity at enrollment as per NCI-CTCAE version 5.0 criteria.

Known HIV infection or active hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive) infection.

Presence of indwelling catheters or drainage tubes (e.g., biliary drainage tubes or thoracic/abdominal drainage tubes or pericardial catheters). Use of specialized central venous catheters is permitted.

Severe malnutrition (for patients <70 years, BMI <18.5 kg/m^2; for patients ≥70 years, BMI <20 kg/m^2).

History of severe allergic reactions to key therapeutic agents in this study (including fludarabine, cyclophosphamide, mesna, tocilizumab, and anti-infective drugs used during preconditioning).

History of disseminated intravascular coagulation (DIC), deep vein thrombosis, or pulmonary embolism within 6 months prior to enrollment.

History of autoimmune diseases that cause terminal organ damage or require systemic immunosuppressive/systemic disease-modifying drugs within 2 years prior to enrollment (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus).

Any disease that may interfere with the safety or efficacy assessment of the study treatment.

Female participants who are unwilling to use contraception from the time of consent until 6 months after completing CAR-T cell infusion.